A Multipronged Approach Can Address Disparities in Cancer Care for Patients in Rural Communities

October 27, 2024 9:00 am

by Kyle Doherty

Investigators are examining and implementing several innovations that they hope will combat the persistent issue of limited access to cancer care for patients living in rural areas, including programs aimed at increasing clinical trial enrollment for these … Read more

Discovery of new mechanism explains how ovarian cancer disables immune cells

October 23, 2024 9:00 am

by Weill Cornell Medical College

Weill Cornell Medicine researchers have discovered a mechanism that ovarian tumors use to cripple immune cells and impede their attack—blocking the energy supply T cells depend on. The work, published Oct. 23 in Nature, … Read more

Avutometinib Combo Yields Responses in Low-Grade Serous Ovarian Cancer

October 18, 2024 9:00 am

Clearity’s Perspective: If you or someone you love has been diagnosed with low-grade serous ovarian cancer (LGSOC), consider watching the recording of the OC Education webinar, “But This is Different: Understanding and Getting Support for the Unique Needs of People Read more

Communication gaps among clinicians may limit conversations about prognosis, hospice

October 16, 2024 9:00 am

Clearity’s Perspective: As this article highlights, it is important to know that you can bring up questions or concerns related to your prognosis with someone on your care team. Instead of waiting for the doctor to bring this topic up, Read more

Returning To Work After Ovarian Cancer

October 10, 2024 9:00 am

Clearity Perspective: For some people diagnosed with ovarian cancer, an important part of their “new normal” is returning to work. This can present opportunities and challenges. The impacts of cancer, surgery, and side effects from treatment may make re-entering the Read more

Conversation with an End-of-Life Doula

October 10, 2024 9:00 am

Danielle Peterson, Clearity’s Director of Education, talks with End-of-Life Doula, Vanessa Johnson, about planning for end-of-life, considerations for a ‘good death,’ and how she compassionately meets individuals and families at the end of life.

 

Danielle: Vanessa Johnston, thank you … Read more

Sylvester Researchers Expand Ovarian Cancer Study to Africa

September 23, 2024 9:00 am

by Lauren Comander

Sophia George, Ph.D., and Matthew Schlumbrecht, M.D., M.P.H., are taking on the world of ovarian cancer research. As researchers for Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, the duo is

Read more

TORL-1-23 Generates Responses in Heavily Pretreated CLDN6-Positive Solid Tumors

September 15, 2024 9:00 am

by Chris Ryan

TORL-1-23, a Claudin-6 (CLDN6)–targeted antibody-drug conjugate (ADC), led to responses in patients with heavily pretreated, CLDN6-positive advanced solid tumors, including platinum-resistant ovarian cancer. Additionally, the agent was well tolerated, according to data from the phase 1 TORL-123-001 … Read more

Dr Angeles Alvarez Secord on “Exciting” Responses With Mirvetuximab Soravtansine in Platinum-Sensitive Ovarian Cancer

September 15, 2024 9:00 am

by Rose McNulty

Mirvetuximab soravtansine showed promise for patients with heavily pretreated FRα-positive, platinum-sensitive ovarian cancer—a challenging patient population to treat—in the phase 2 PICCOLO trial. New data from the study presented at the European Society for Medical Oncology (ESMO) … Read more

Dato-DXd Shows Promising Efficacy in Endometrial and Ovarian Cancer

September 15, 2024 9:00 am

by Jason M. Broderick

The TROP2-directed antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) showed promising antitumor activity with manageable toxicity in patients with advanced/metastatic ovarian and endometrial cancer and progressive disease following platinum chemotherapy, according to results from the phase 2 TROPION-PanTumor03 … Read more

Five-year PFS results show advantage for niraparib maintenance in patients with advanced ovarian cancer, with no OS benefit

September 14, 2024 9:00 am

At the ESMO Congress 2024 (Barcelona, 13–17 September), final overall survival (OS) data after a median follow-up of approximately 6 years revealed no benefit of niraparib maintenance over placebo for patients newly diagnosed with advanced ovarian cancer at high risk … Read more

Medical Professionals Can Get Cancer Too – Part 2

September 11, 2024 11:00 am

By Linda Winkler Garvin

Clearity’s Perspective: Linda Winkler Garvin has a Masters degree in nursing, adult nurse practitioner training, and over 30 years of healthcare experience. Her story is an example of how even those with a medical background may … Read more

Medical Professionals Can Get Cancer Too – Part 1

September 11, 2024 9:00 am

By Linda Winkler Garvin

Clearity’s Perspective: Linda Winkler Garvin has a Masters degree in nursing, adult nurse practitioner training, and over 30 years of healthcare experience. Her story is an example of how even those with a medical background may … Read more

Balancing Hope and Reality After a Cancer Diagnosis

September 6, 2024 9:00 am

by Barbra Williams Cosentino

If your doctor said, “I’m very sorry, but your cancer is terminal,” you’d obviously be devastated. What if she then added, “The prognosis is that you have about six months left, but with treatments we can … Read more

Ovarian cancer discovery: Targetable variant RAD51D found in Chinese patients

August 21, 2024 9:00 am

by BGI Genomics

Researchers from BGI Genomics and Fudan University have published new findings on ovarian cancer (OV) among Chinese patients in JCO Global Oncology.

The study revealed the germline mutational landscape of Chinese patients with OV and identified … Read more

ASCO Releases Statement on Recommendations to Improve Accessibility to Cancer Clinical Trials

August 14, 2024 9:00 am

by Kyle Doherty

A research statement was published by the American Society of Clinical Oncology (ASCO) that describes 4 recommendations for decentralization to improve accessibility of cancer clinical trials.1,2

In the statement, the ASCO panel recommended that the FDA … Read more

‘Symptom triggered’ testing can pick up early-stage aggressive ovarian cancer in 1 in 4 of those affected

August 13, 2024 9:00 am

by University of Birmingham

A study published in the International Journal of Gynecological Cancer found that the UK’s protocol for picking up early-stage disease in women with high grade serous ovarian cancer—the most common, aggressive, and lethal form of the … Read more

Review Highlights the Need to Increase Germline BRCA Mutation Testing in Males

August 12, 2024 9:00 am

by Jax DiEugenio

Although the risks of cancer developing in females harboring germline BRCA1or BRCA2 mutations are understood and have propelled genetic testing and preventative measures for this population, more work is required to amplify the rates of this … Read more

Study Finds Higher Rates of Hereditary Cancer Mutations in Minority Populations Missed by Current Screening Guidelines

July 24, 2024 9:00 am

by IPM staff

A new study from the Mayo Clinic finds that current screening protocols fail to catch a significant number of individuals with genetic mutations linked to hereditary breast and ovarian cancer syndrome (HBOC) and Lynch syndrome, which increase … Read more